BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34727304)

  • 21. Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.
    Nakamura Y; Hattori N; Iida N; Yamashita S; Mori A; Kimura K; Yoshino T; Ushijima T
    Cancer Lett; 2017 Aug; 402():100-109. PubMed ID: 28576751
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of a novel class of B-Raf(V600E)-selective inhibitors through virtual screening and hierarchical hit optimization.
    Kong X; Qin J; Li Z; Vultur A; Tong L; Feng E; Rajan G; Liu S; Lu J; Liang Z; Zheng M; Zhu W; Jiang H; Herlyn M; Liu H; Marmorstein R; Luo C
    Org Biomol Chem; 2012 Sep; 10(36):7402-17. PubMed ID: 22875039
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 2-Anilinoquinoline based arylamides as broad spectrum anticancer agents with B-RAF
    El-Damasy AK; Haque MM; Park JW; Shin SC; Lee JS; EunKyeong Kim E; Keum G
    Eur J Med Chem; 2020 Dec; 208():112756. PubMed ID: 32942186
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Context-dependent roles of mutant B-Raf signaling in melanoma and colorectal carcinoma cell growth.
    Hao H; Muniz-Medina VM; Mehta H; Thomas NE; Khazak V; Der CJ; Shields JM
    Mol Cancer Ther; 2007 Aug; 6(8):2220-9. PubMed ID: 17699719
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.
    Zhang P; Kawakami H; Liu W; Zeng X; Strebhardt K; Tao K; Huang S; Sinicrope FA
    Mol Cancer Res; 2018 Mar; 16(3):378-389. PubMed ID: 29233910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
    Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
    Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity.
    Tsai J; Lee JT; Wang W; Zhang J; Cho H; Mamo S; Bremer R; Gillette S; Kong J; Haass NK; Sproesser K; Li L; Smalley KS; Fong D; Zhu YL; Marimuthu A; Nguyen H; Lam B; Liu J; Cheung I; Rice J; Suzuki Y; Luu C; Settachatgul C; Shellooe R; Cantwell J; Kim SH; Schlessinger J; Zhang KY; West BL; Powell B; Habets G; Zhang C; Ibrahim PN; Hirth P; Artis DR; Herlyn M; Bollag G
    Proc Natl Acad Sci U S A; 2008 Feb; 105(8):3041-6. PubMed ID: 18287029
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer.
    Nucera C; Nehs MA; Nagarkatti SS; Sadow PM; Mekel M; Fischer AH; Lin PS; Bollag GE; Lawler J; Hodin RA; Parangi S
    Oncologist; 2011; 16(3):296-309. PubMed ID: 21355020
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
    Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
    Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of New Quinolone-Based Diarylamides as Potent B-RAF
    Kim HJ; Park JW; Seo S; Cho KH; Alanazi MM; Bang EK; Keum G; El-Damasy AK
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells.
    Goulielmaki M; Koustas E; Moysidou E; Vlassi M; Sasazuki T; Shirasawa S; Zografos G; Oikonomou E; Pintzas A
    Oncotarget; 2016 Feb; 7(8):9188-221. PubMed ID: 26802026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
    Anbar HS; El-Gamal MI; Tarazi H; Lee BS; Jeon HR; Kwon D; Oh CH
    J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1712-1726. PubMed ID: 32962435
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wnt/β-Catenin Pathway Activation Mediates Adaptive Resistance to BRAF Inhibition in Colorectal Cancer.
    Chen G; Gao C; Gao X; Zhang DH; Kuan SF; Burns TF; Hu J
    Mol Cancer Ther; 2018 Apr; 17(4):806-813. PubMed ID: 29167314
    [TBL] [Abstract][Full Text] [Related]  

  • 34. C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).
    Karreth FA; DeNicola GM; Winter SP; Tuveson DA
    Mol Cell; 2009 Nov; 36(3):477-86. PubMed ID: 19917255
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.
    Park S; Kim TM; Cho SY; Kim S; Oh Y; Kim M; Keam B; Kim DW; Heo DS
    Cancer Lett; 2020 Dec; 495():135-144. PubMed ID: 32979462
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer.
    Kawakami H; Huang S; Pal K; Dutta SK; Mukhopadhyay D; Sinicrope FA
    Mol Cancer Ther; 2016 Dec; 15(12):3015-3027. PubMed ID: 27765849
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apoptosis of human melanoma cells induced by inhibition of B-RAFV600E involves preferential splicing of bimS.
    Jiang CC; Lai F; Tay KH; Croft A; Rizos H; Becker TM; Yang F; Liu H; Thorne RF; Hersey P; Zhang XD
    Cell Death Dis; 2010 Sep; 1(9):e69. PubMed ID: 21364673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential sensitivity of melanoma cell lines with differing B-Raf mutational status to the new oncogenic B-Raf kinase inhibitor UI-152.
    Kim YK; Ahn SK; Lee M
    Cancer Lett; 2012 Jul; 320(2):215-24. PubMed ID: 22425959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
    Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
    Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting BRAFV600E in thyroid carcinoma: therapeutic implications.
    Mitsiades CS; Negri J; McMullan C; McMillin DW; Sozopoulos E; Fanourakis G; Voutsinas G; Tseleni-Balafouta S; Poulaki V; Batt D; Mitsiades N
    Mol Cancer Ther; 2007 Mar; 6(3):1070-8. PubMed ID: 17363500
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.